Relevance of the combination of external beam radiotherapy with the hypoxia-activated prodrug ICF05016 in an experimental model of extraskeletal myxoid chondrosarcoma Elise MaubertValérie WeberElisabeth Miot-Noirault PRECLINICAL STUDIES 18 September 2020 Pages: 295 - 303
Epidermal growth factor-like domain multiple 6 (EGFL6) promotes the migration and invasion of gastric cancer cells by inducing epithelial-mesenchymal transition Fu-Chun HuoWen-Tao ZhuJie Mou PRECLINICAL STUDIES 19 September 2020 Pages: 304 - 316
Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy Chie IshikawaMasachika SenbaNaoki Mori PRECLINICAL STUDIES 21 September 2020 Pages: 317 - 329
Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study Jie LiuYao-Tiao DengYu Jiang PRECLINICAL STUDIES 24 September 2020 Pages: 330 - 336
Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis Tian ZhaoYujie LiuAipo Diao PRECLINICAL STUDIES 25 September 2020 Pages: 337 - 347
Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma Nadire ÖzenverSara AbdelfatahThomas Efferth PRECLINICAL STUDIES Open access 25 September 2020 Pages: 348 - 361
The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway Linping LeiXuqin XieZongguang Zhou PRECLINICAL STUDIES 26 September 2020 Pages: 362 - 376
rAj-Tspin, a novel recombinant peptide from Apostichopus japonicus, suppresses the proliferation, migration, and invasion of BEL-7402 cells via a mechanism associated with the ITGB1-FAK-AKT pathway Ping YuRui WuLi Lv PRECLINICAL STUDIES 28 September 2020 Pages: 377 - 385
Discovery of oxyepiberberine as a novel tubulin polymerization inhibitor and an anti-colon cancer agent against LS-1034 cells Hanbing NingWenquan LuHongtao Wen PRECLINICAL STUDIES 30 September 2020 Pages: 386 - 393
Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy Zhiqiang WuWenbo GuoWenquan Zhuang PRECLINICAL STUDIES Open access 01 October 2020 Pages: 394 - 399
Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities Sayuri Nakamura-BencomoDenisse A. GutierrezArmando Varela-Ramirez PRECLINICAL STUDIES 16 October 2020 Pages: 400 - 415
Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling Minan LuKegong XieYujin Tang PRECLINICAL STUDIES 30 October 2020 Pages: 416 - 425
A decision process for drug discovery in retinoblastoma María Belen CancelaSantiago ZugbiPaula Schaiquevich PRECLINICAL STUDIES 16 November 2020 Pages: 426 - 441
Selective targeting of the androgen receptor-DNA binding domain by the novel antiandrogen SBF-1 and inhibition of the growth of prostate cancer cells Ahmed ElgehamaLijun SunQiang Xu PRECLINICAL STUDIES 07 January 2021 Pages: 442 - 457
Downregulation of breast cancer resistance protein by long-term fractionated radiotherapy sensitizes lung adenocarcinoma to SN-38 Yuqing WangJie HuangShirong Zhang PRECLINICAL STUDIES 21 January 2021 Pages: 458 - 468
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors Toshihiko DoiMasaomi TajimiYoichi Naito PHASE I STUDIES Open access 16 September 2020 Pages: 469 - 476
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer Jin-Ji YangJian FangYi-Long Wu PHASE I STUDIES 14 October 2020 Pages: 477 - 487
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors Xiaofei ZhouFarhad SedaratiZsuzsanna Papai PHASE I STUDIES Open access 22 October 2020 Pages: 488 - 498
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer Benjamin A. GartrellMack Roach IIIHoward I. Scher PHASE II STUDIES Open access 13 September 2020 Pages: 499 - 508
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer Clinton YamGaiane M. RauchStacy L. Moulder PHASE II STUDIES 28 September 2020 Pages: 509 - 515
Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study Zhi-Qiang WangDe-Shen WangYu-Hong Li PHASE II STUDIES 18 October 2020 Pages: 516 - 523
Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer Yimeng ChenBaoshi BaoWeihong Zhao PHASE II STUDIES 02 November 2020 Pages: 524 - 529
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320) Sakiko OtaniJiichiro SasakiNoriyuki Masuda PHASE II STUDIES 07 November 2020 Pages: 530 - 536
Comment on: an orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent Xinxiao LiRenba Liang Review 29 October 2020 Pages: 537 - 537
Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer Bartosz Mateusz GąsiorkiewiczPaulina Koczurkiewicz-AdamczykElżbieta Pękala Review Open access 07 November 2020 Pages: 538 - 563
Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma Shigemasa TakamizawaYoshitaka HonmaSeiichi Yoshimoto Short Report 17 September 2020 Pages: 564 - 570
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma Hiroaki KodamaKazushige WakudaToshiaki Takahashi Short Report 21 September 2020 Pages: 571 - 577
Glochidiol, a natural triterpenoid, exerts its anti-cancer effects by targeting the colchicine binding site of tubulin Hongjie ChenLijun MiaoHong Liu Short Report 07 October 2020 Pages: 578 - 586
The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells Dalal AlSultanEmma KavanaghMichael J Duffy Short Report 14 October 2020 Pages: 587 - 594
Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma Masahide FukudoGaku TamakiYoshikazu Tasaki Short Report 23 October 2020 Pages: 595 - 604
A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel Kei SaitoYousuke NakaiKazuhiko Koike Short Report 23 October 2020 Pages: 605 - 613